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Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 fusion gene, resulting in uncontrolled proliferation of myeloid progenitor cells. Growth factor independence 1 (GFI1) is a transcription factor with a crucial role in haematopoiesis, including preserving haematopoietic stem cell (HSC) quiescence and enhancing granulocytic differentiation, but is not required for inducing myeloid differentiation in p210BCR/ABL-transformed cells. 1 Recently, Soliera et al. 2 demonstrated that ectopic GFI1 expression inhibited proliferation and colony formation both in p210BCR/ABLexpressing cell lines and in primary CD34 þ CML cells through the repression of STAT5B and/or Mcl-1. This study, along with their previous work 1 demonstrated the biological importance of the GFI1/STAT5B/Mcl-1 regulatory pathway on proliferation and survival of CML cells. However, the association between GFI1 expression and the achievement of response to imatinib therapy, be it major molecular response (MMR; o0.1% BCR-ABL1 (IS)) or early molecular response (BCR-ABL1 p10% following 3 months of imatinib therapy) in de-novo chronic phase-CML (CP-CML) patients has not been examined. We hypothesized, based on the findings of Soliera et al. that increased GFI1 expression would be associated with a favorable outcome in CP-CML treated with imatinib.
The expression of GFI1 was examined using TaqMan Low Density array (RQ-PCR, Applied Biosystems, Carlsbad, CA, USA) in white blood cells of 40 de-novo CP-CML patients enrolled in clinical trials conducted in our Centre, who received imatinib as frontline therapy. Data analysis was performed using the statistical program R version 2.15.1, with the Bioconductor package high-throughput analysis and visualization of quantitative realtime PCR (HTqPCR) 3 and GraphPad Prism 5. GFI1 expression (Hs00382207_m1, Applied Biosystems) was normalized to GUSB expression (Hs99999908_m1, Applied Biosystems) using the DDCt method. 4 As GFI1 is primarily expressed in granulocytes, 5 we rationalized that the use of white cells would enable accurate representation of total GFI1 expression from each patient.
Accepted article preview online 15 February 2013; advance online publication, 8 March 2013 Letters to the Editor We first examined whether there was differential expression of GFI1 at diagnosis, in those patients who transformed to blast crisis (BC; time range: 3.7-13 months, n ¼ 6) while receiving imatinib as frontline therapy (Figure 1a) . A significant decrease in GFI1 expression at diagnosis was observed in patients who transformed to BC on imatinib therapy, compared with those who did not (n ¼ 37, P ¼ 0.002), suggesting that lower GFI1 expression is associated with the transformation in CML. Furthermore, receiver-operator characteristic analysis revealed that de-novo CP-CML patients with GFI1 DCto À 2.782 (92% specificity and 83% sensitivity; P ¼ 0.0036, likelihood ratio ¼ 10.28) are B10 times more likely to transform to BC. To determine whether the observed variation in GFI1 expression between patients could be attributable to differences in cell populations, we examined the correlation between GFI1 expression and differential cell count information available in 32 patients. No significant correlation (P40.05) was observed between the total white cell count, or absolute blast, granulocyte, lymphocyte or monocyte numbers, and GFI1 expression (data not shown). Additionally, no significant correlation was observed between GFI1 expression and blast cell percentage (data not shown). We also examined the impact of tyrosine-kinase inhibitor treatment on GFI1 expression in vivo by comparing the expression in blood collected after the first 8 days of imatinib therapy (n ¼ 12; including three patients who later transformed to BC), with that collected from the same patients at diagnosis. Overall, we observed a significant decrease in GFI1 expression in all patients after 8 days of imatinib therapy (Po0.0001), consistent with the previously published results of Huang et al. 6 Importantly, this decrease was observed in both the patients who transformed to BC (n ¼ 3, P ¼ 0.02) and those who did not (n ¼ 9, P ¼ 0.0005; data not shown).
We next examined the expression of GFI1 in CP-CML patients who did, or did not, achieve MMR (o0.1% BCR-ABL1 levels) by 12 months. Intriguingly, there was no statistically significant difference observed in GFI1 expression (P ¼ 0.35; Figure 1b ) between these patients, nor when the response end point was extended to 24 months ( Figure 1c ). We then determined whether GFI1 expression was instead a biomarker for the achievement of BCR-ABL1 transcript levels of p10% (IS) at 3 months, a time-point recently demonstrated to be predictive of longer-term response in imatinib-treated patients. 7 However, again there was no significant difference observed in GFI1 expression between patients with 3-month BCR-ABL1 transcript levels p10% (good response) and those with levels 410% (poor response; Figure 1d ).
The organic cation transporter-1 (OCT-1) activity assay, which measures the functional activity of the OCT-1 protein, the major active transporter involved in imatinib disposition in CML cells, using patient mononuclear cells (MNC) at diagnosis, is also a strong prognostic indicator. 8 In particular, patients with very low OCT-1 activity (OA) (p4 ng/200 000 cells) are at significant risk of poor molecular response, mutation development and leukemic transformation on imatinib therapy. 9 To determine whether GFI1 expression was associated with OA in this cohort of CP-CML patients, we grouped patients according to their OA into low (p4 ng/200 000 cells) and high (44 ng/200 000 cells) groups. There was no statistically significant difference (P ¼ 0.96; Figure 1e ) in GFI1 expression, suggesting that GFI1 expression has no role in OA.
Point mutations in the kinase domain (KD) of BCR-ABL1 are the most prevalent mechanism of acquired resistance to kinase inhibitor therapy in CML patients. 10 Therefore, the relationship between mutation development and GFI1 expression in our cohort of patients with mutations (n ¼ 4, within 24 months) was Letters to the Editor assessed (Figure 1f) , however, no significant association was observed. Finally, patients were grouped according to their Sokal score (low, medium or high), as previously defined, 11 but again no significant difference with respect to GFI1 expression was observed between these groups (Figure 1g) .
We further examined GFI1 expression in MNC from 93 de-novo CP-CML patients. There was no significant difference in GFI1 expression between patients who achieved MMR by 12 months (P ¼ 0.43; Figure 2a ), or by 24 months (P ¼ 0.91; Figure 2b ), and those who didn't. Again, as seen in the analysis of white cells, no significant association between GFI1 expression and the achievement of 3-month BCR-ABL1 transcript levels (P ¼ 0.96; Figure 2c ), OA (P ¼ 0.46; Figure 2d ), BCR-ABL1 KD mutation development (P ¼ 0.18; Figure 2e ) or Sokal score (P ¼ 0.88; Figure 2f ) was observed.
As GFI1 has a role in HSC maintenance, and the biological importance of GFI1 was originally determined in CD34 þ cells by Soliera et al., 2 we examined GFI1 expression in CD34 þ cells from CP-CML patients. To do this, the McWeeney et al. 12 (GSE14671) microarray data set involving CD34 þ cells from 59 primary CP-CML patients originally generated to identify genes associated with imatinib response was reanalysed for GFI1 expression. There was no significant difference in GFI1 expression between imatinib responders (patients who achieved at least partial cytogenetic response within 12 months of therapy) and nonresponders (all other patients) in CP-CML CD34 þ cells (P ¼ 0.28; Figure 2g ). Taken together, these data suggest that GFI1 expression levels are not significantly altered in cases of imatinib resistance, regardless of the cell type examined.
As our preliminary data identified that decreased GFI1 expression was associated with CML transformation, we interrogated the Radich et al. 13 microarray data set (GSE4170) to investigate the expression of GFI1 in CP (n ¼ 42; defined as o10% blasts), accelerated phase (AP, n ¼ 17; defined as 10-30% blasts or o10% blasts with clonal evolution) and BC-CML (n ¼ 26; defined as 430% blasts). Interestingly, the material from CML patients in BC had significantly lower GFI1 expression compared with CP-CML (Po0.001; Figure 2h ) and AP-CML (Po0.001; Figure 2h ), supporting our observation that decreased GFI1 expression is associated with progression in CML. When we compared the GFI1 expression of patients in BC versus BC patients who were now in remission after chemotherapy (non-matched samples, BC-rem; n ¼ 3), we observed a significant increase in GFI1 expression in the BC-rem patients (P ¼ 0.009; Figure 2i ) to levels comparable with CP-CML (P ¼ 0.33; Figure 2i ). Furthermore, these data are in keeping with the lower GFI1 expression we observed in our cohort of de-novo CP-CML patients who later transformed to BC. However, it must be noted that an independent study of larger sample size is required to confirm our observation that low GFI1 expression at diagnosis may be associated with transformation and progression to BC in CML.
This work supports the previously described role of GFI1 in inhibition of proliferation and colony formation of p210BCR/ABLtransformed cells and primary CD34 þ CML cells; 2 blockade of granulopoiesis in GFI1 À / À myeloid progenitors via elevated levels of HoxA9, Pbx1 and Meis1; 14 and the development of myelo-proliferative disease 15 and defects to T-cell development 12 microarray data set (*** Po0.001), and (i) CML patients in CP, BC or BC patients who achieved remission after chemotherapy (n ¼ 3; **Po0.01, Mann-Whitney). N.S. indicates not significant (P40.05). All statistical analyses were performed using a two-tailed t-test, unless otherwise stated. Box plots indicate the interquartile range (25-75%) around the median. Whiskers represent the 10th and 90th percentiles.
in GFI1 À / À mice. Taken together, our results suggest that unlike other negative prognostic markers (such as OA, BCR-ABL1 transcript levels at 3 months and Sokal score), low GFI1 expression correlates selectively with a high risk of early transformation to BC, but not mutation development, primary resistance or secondary resistance in CP-CML patients.
Increased circulating IL-2Ra (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine-phenotype study The clinical phenotype of systemic mastocytosis (SM) is highly variable; establishing prognosis in individual patients is not trivial. The classification of adult SM patients per the 2008 World Health Organization (WHO) system 1 has been validated for its prognostic utility. 2 In addition to WHO SM subtype, an independent association between inferior survival and advanced age, weight loss, anemia, thrombocytopenia, hypoalbuminemia and excess bone marrow (BM) blasts has been demonstrated. 2 Aside from advanced age, however, the aforementioned parameters are typically applicable only to patients with advanced SM subtypes (that is aggressive SM (ASM), SM associated with clonal non-mast cell lineage disease (SM-AHNMD) or mast cell leukemia). In contrast, patients with indolent SM (ISM) have a normal life expectancy; their risk of transformation to acute leukemia or ASM has been estimated to be 1% and 3%, respectively. 3, 4 Predictors of disease progression include advanced age, increased serum b2-microglobulin level and multilineage presence of KITD816V. Recent studies in primary myelofibrosis, 5 myelodysplastic syndrome 6 and diffuse large B-cell lymphoma 7 have demonstrated an abnormal circulating cytokine milieu reflecting the host response to clonal proliferation. In these studies, specific cytokines were found to be prognostically relevant, independent of known disease-specific prognostic factors. Here, we conducted a comprehensive analysis of circulating cytokines/chemokines with clinicopathologic and clinical outcome correlations in a cohort of SM patients.
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